Testosterone Cypionate and Erythrocytosis: When Elevated Hematocrit Won't Go Away

Print or save as PDFOpens the printable lab tracker and your print dialog. No sign-up.

How often does hematocrit stay elevated on testosterone cypionate?

Erythrocytosis is described as the most common side effect of testosterone therapy in a 2023 clinical guide [3], and a 2018 review reports the highest incidence with short-acting injectable formulations [5]. The size of the effect has been measured best in aggregate. A Bayesian network meta-analysis of 29 placebo-controlled randomized trials covering 3,393 men found that intramuscular testosterone enanthate or cypionate raised mean hematocrit by 4.0% over placebo (95% CI 2.9 to 5.1) [4]. Gel raised it 3.0%, oral testosterone undecanoate 4.3%, intramuscular testosterone undecanoate 1.6%, and patch 1.4% [4]. Only the patch differed significantly from intramuscular enanthate/cypionate; the other pairings did not [4].

Threshold-based rates come from a single-center retrospective review of 178 hypogonadal men followed for 3 years: hematocrit above 50% occurred in 66.7% of men on injectable testosterone, 12.8% of men on gels and 35.1% of men on pellets [6]. The injection group was younger (mean 42.5 years versus about 54), had a higher baseline hematocrit, and the study was not randomized [6]. A 2025 systematic review of drug-induced erythrocytosis reported rates up to 66.7% among men on prescription testosterone, with intramuscular formulations, higher doses and older age associated with greater risk [1].

Why the hematocrit rises

The Depo-Testosterone label states that androgens have been reported to stimulate red blood cell production by enhancing production of erythropoietic stimulation factor [2]. A 2018 review lists the proposed mechanisms as hepcidin and iron handling, erythropoietin production, bone marrow stimulation and genetic factors [5]. The hepcidin arm has been studied in mice: testosterone administration downregulated hepatic hepcidin expression, upregulated renal erythropoietin expression and increased iron incorporation into red blood cells [7]. A 2015 review reports that injectables raise hemoglobin and hematocrit the most among formulations [8].

What the Depo-Testosterone label says

The Depo-Testosterone label (testosterone cypionate, intramuscular) says to check hemoglobin and hematocrit periodically in long-term use and lists polycythemia among hematologic adverse reactions [2]. It notes that an increase in red blood cell mass may increase the risk of thromboembolic events, and says that venous thromboembolism has been reported with testosterone products and that treatment should be discontinued if one is suspected [2]. The Endocrine Society guideline recommends against starting testosterone therapy in men who already have an elevated hematocrit, and recommends monitoring hematocrit during the first year of treatment [15].

Does lowering the dose or switching formulation help?

A 2022 review says clinicians will often reduce the dose, stop therapy, order phlebotomy, or combine these [9]. One clinical consultation guide states that therapy should be decreased or discontinued while hematocrit is above 54% until it normalizes [3].

On formulation, the clearest comparison is the network meta-analysis: patch raised hematocrit 1.4% versus 4.0% for intramuscular cypionate/enanthate, and that was the only significant difference among the pairings tested [4]. Gel at 3.0% was not significantly different from the injectable [4]. The retrospective review described above found far less erythrocytosis with gels than injections, but its groups differed in age and starting hematocrit [6].

Phlebotomy, and what is actually proven

For erythrocytosis that is not polycythemia vera, a 2025 hematology review says phlebotomy should be considered for symptom control, cytoreductive therapy should be avoided, cardiovascular risk factors should be optimized and low-dose aspirin is advised [10]. A second 2025 review says there are no evidence-based treatment guidelines for JAK2 wild-type erythrocytosis, and that low-dose aspirin and/or phlebotomy might be considered on an individualized basis when there are hyperviscosity symptoms, cardiovascular comorbidities or a history of thrombosis, with frequency determined by symptom relief [11]. Neither review is specific to testosterone. Polycythemia vera is handled differently: a 2021 review says all patients with PV require phlebotomy to keep hematocrit below 45% and aspirin 81 mg once or twice daily, absent contraindications [12].

Is a persistently high hematocrit dangerous?

In the general population, higher hematocrit tracks with venous thrombosis. In the Tromso study of 26,108 adults, each 5% increment in hematocrit carried a hazard ratio of 1.25 for total venous thromboembolism (95% CI 1.08 to 1.44), and men with hematocrit of 46% or higher (the upper 20th percentile) had a 1.5-fold increased risk of total VTE and a 2.4-fold increased risk of unprovoked VTE compared with men in the lower 40th percentile [13]. That study was not about testosterone.

TRAVERSE tested a daily 1.62% testosterone gel, not cypionate injections, in 5,246 men with hypogonadism and cardiovascular risk, and pulmonary embolism was reported in 0.9% of the testosterone group versus 0.5% on placebo [14]. Reviews describe the link between testosterone-related erythrocytosis and blood clots as unclear or inconclusive [5][8]. A 2025 systematic review reported thromboembolic events in up to 2.7% of men on testosterone therapy [1].

What else is considered when it does not come down

The most clinically relevant step in the workup of erythrocytosis is excluding polycythemia vera with JAK2 mutation screening [11]. Acquired erythrocytosis not due to drugs comes from hypoxia such as cardiopulmonary disease or renal artery stenosis, and from erythropoietin-producing tumors [10]. Serum erythropoietin is variably informative [10], and a subnormal level suggests an erythropoietin receptor mutation [11].